Anti-Human CD2 (LO-CD2a) – Dylight® 650

Anti-Human CD2 (LO-CD2a) – Dylight® 650

Product No.: C542

[product_table name="All Top" skus="C1839"]

- -
- -
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
LFA-2, T11, SRBC, BTI-322
Rat IgG2b κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Purified human T Lymphocytes
Product Concentration
2.0 mg/ml
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Storage and Handling
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
2-8°C Wet Ice
Excitation Laser
Red Laser (652 nm)
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2.
Human CD2 is a 351 amino acid transmembrane glycoprotein that is part of the immunoglobulin superfamily1, 2. CD2 is expressed on the surface of mature T cells, most NK cells, thymocytes, dendritic cells, and 9-12% of bone marrow cells. CD2 participates in T cell and NK cell activation and is important for thymocyte development and assembly of the immunological synapse1. However, the role of CD2 in murine immunity is not always consistent with its function in higher animals. CD2 is known to bind to lymphocyte-associated antigen3 (CD58 and its murine analog CD48) as well as CD59.

LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation3, 4. LO-CD2a strongly inhibits mixed lymphocyte culture3 and induces T cell apoptosis5. Additionally, LO-CD2a induces very low levels of cytokine release, inhibits cytokine production induced by OKT3, and induces human T cell hyporesponsiveness3. The immune response is inhibited as a result of cell lysis by antibody-dependent cell mediated cytotoxicity (ADCC) induced by NK cells and activated monocytes and from CD2 down-modulation on CD2+ cells6. LO-CD2a also strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3. LO-CD2a has demonstrated immunosuppressive activity in vitro and effective T cell depletion in vivo. Unresponsiveness upon restimulation with the same antigen makes LO-CD2 distinct from other anti-CD2 antibodies7.
Antigen Distribution
CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells.

Antigen Details

CD58 (LFA-3), CD48, CD59, CD15
NCBI Gene Bank ID
Research Area

References & Citations

1. Binder C, Cvetkovski F, Sellberg F, et al. Front Immunol. 11:1090. 2020.
2. Bierer BE, Sleckman BP, Ratnofsky SE, et al. Annu Rev Immunol. 7:579–599. 1989.
3. Latinne D, De La Parra B, Nizet Y, et al. Int Immunol. 8(7):1113-1119. 1996.
4. Bazin H, Latinne D, et al, inventors; Biotransplant Inc, assignee. LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation. US patent 6,849,258 B1. Feb 1, 2005.
5. Dumont C, Déas O, Mollereau B, et al. J Immunol. 160(8):3797-3804. 1998.
6. Nizet Y, Chentoufi AA, de la Parra B, et al. Transplantation. 69(7):1420-1428. 2000.
7. Xu Y, Kolber-Simonds D, Hope JA, et al. Clin Exp Immunol. 138(3):476-483. 2004.
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.